Utilizing chemokines in cancer immunotherapy.

Chemokines / metabolism Humans Immunotherapy Immunotherapy, Adoptive Neoplasms / therapy Tumor Microenvironment
CAR T cells antibodies cancer vaccines chemokines inhibitors oncolytic viruses

Journal

Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956

Informations de publication

Date de publication:
08 2022
Historique:
received: 25 02 2022
revised: 30 03 2022
accepted: 01 04 2022
pubmed: 3 5 2022
medline: 23 7 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro- and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunotherapy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies.

Identifiants

DOI: 10.1016/j.trecan.2022.04.001 PMID: 35501268
pubmed: 35501268
pii: S2405-8033(22)00087-5
doi: 10.1016/j.trecan.2022.04.001
pii:
doi:

Substances chimiques

Chemokines 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

670-682

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests S.K. has received honoraria from TCR2 Inc., Novartis, BMS and GSK. S.K. and S.E. are inventors of several patents in the field of immuno-oncology. S.K. and S.E. received license fees from TCR2 Inc. and Carina Biotech. S.K. and S.E. received research support from TCR2 Inc. and Arcus Bioscience for work unrelated to the manuscript.

Auteurs

Florian Märkl (F)

Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.

Duc Huynh (D)

Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany.

Stefan Endres (S)

Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany.

Sebastian Kobold (S)

Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany. Electronic address: Sebastian.kobold@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Chimiokines › Utilizing chemokines in cancer immunotherapy.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Utilizing chemokines in cancer immunotherapy.
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Utilizing chemokines in cancer immunotherapy.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Utilizing chemokines in cancer immunotherapy.
questionsmedicales.fr › Tumeurs › Utilizing chemokines in cancer immunotherapy.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Utilizing chemokines in cancer immunotherapy.